Skip to content

efficacy of sclerotherapy for treatment of achalasia

Study of the effectiveness of Sclerotherapy for treatment of idiopathic achalasia cases which are resistance to or have poor candidate of pneumatic balloon dilation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT138903234170N1
Enrollment
13
Registered
2011-01-20
Start date
2007-06-24
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

idiopathic achalasia. Achalasia of cardia

Interventions

We have used 10cc of Ethanole amine oleat 2.5% divided in four parts and injected into 4 quadrants of LES (about 2 cm above Z-line) ..
Treatment - Drugs
We have used 10cc of Ethanole amine oleat 2.5% divided in four parts and injected into 4 quadrants of LES (about 2 cm above Z-line) .

Sponsors

Research assistance of Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion: poor candidate of PDT(sigmoid esophagus,epipherenic diverticula ,patients with poor operative risk, patients with poor cooperative history for PDT or surgery),Idiopathic achalasia,resistance to PDT,cooperative patients. Exclusion :patients with poor cooperation,secondary achalasia,good response to PDT or other standard therapy,pregnancy or breast feeding, active illicit drug or alcohol abuse, prior history of allergic reactions to agents belonging to the EO family, pregnancy or breast feeding; a history of severe co-morbid disease. Informed consent was obtained from each patient included in the study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Clinical resonse (clinical symptoms). Timepoint: pretreatment and 1.5, 3, 6, 9 and 12 months after thelast injection. Method of measurement: Questionnaire.;Barium volume (cubic ml)in 5th minute. Timepoint: pretreatment/post treatment (1.5-6-12months after last injection). Method of measurement: timed barium esophagogarm.;Barium height(mm)in 5th minute. Timepoint: pretreatment/post treatment(1.5-6-12months after last injection). Method of measurement: timed barium esophagogarm.

Secondary

MeasureTime frame
Perforation or bleeding of injection site. Timepoint: during injection. Method of measurement: endoscopy.;Esophagitis. Timepoint: during injection. Method of measurement: endoscopy.;Chest pain. Timepoint: first 24 hours after each injection. Method of measurement: observation and history taking.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Javad Mikaeli –Dr. Ramin Niknam

Tehran University of Medical Sciences

mikaeli@ams.ac.ir; niknam@ddrc.ac.ir+98 21 8241 5110

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026